Bevacizumab: Difference between revisions
imported>Howard C. Berkowitz mNo edit summary |
imported>Howard C. Berkowitz No edit summary |
||
| Line 2: | Line 2: | ||
'''Bevacizumab''' is an "anti-VEGF (i.e., [[vascular endothelial growth factor A]] ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_001020537 Entrez protein]) [[monoclonal antibody]] consisting of humanized [[murine]] antibody with antigen-binding, complementary-determining regions from murine VEGF".<ref>{{MeSH|Bevacizumab [Substance Name]}}</ref> In the United States, it is marketed as '''Avastin''' by [[Genentech]], a subsidiary of [[Roche Laboratories]] as an [[antineoplastic agent]]. | '''Bevacizumab''' is an "anti-VEGF (i.e., [[vascular endothelial growth factor A]] ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_001020537 Entrez protein]) [[monoclonal antibody]] consisting of humanized [[murine]] antibody with antigen-binding, complementary-determining regions from murine VEGF".<ref>{{MeSH|Bevacizumab [Substance Name]}}</ref> In the United States, it is marketed as '''Avastin''' by [[Genentech]], a subsidiary of [[Roche Laboratories]] as an [[antineoplastic agent]]. | ||
==Indications== | ==Indications== | ||
The U.S. Food and Drug Administration (FDA) recognizes it as indicated for: [[glioma|glioblastoma multiforme]], metastatic [[breast cancer|breast carcinoma]], metastatic [[colorectal cancer]], [[lung cancer|non-small cell lung cancer]], and [[renal cell cardinoma]]. Common unlabeled uses are in [[astrocytoma|anaplastic astrocytoma]] and [[ovarian | The U.S. Food and Drug Administration (FDA) recognizes it as indicated for: [[glioma|glioblastoma multiforme]], metastatic [[breast cancer|breast carcinoma]], metastatic [[colorectal cancer]], [[lung cancer|non-small cell lung cancer]], and [[renal cell cardinoma]]. Common unlabeled uses are in [[astrocytoma|anaplastic astrocytoma]] and [[ovarian carcinoma]]. <ref name=Medscape-Intro>{{citation | ||
| url = http://www.medscape.com/druginfo/dosage?cid=med&drugid=78649&drugname=AVASTIN+IV&monotype=default | | url = http://www.medscape.com/druginfo/dosage?cid=med&drugid=78649&drugname=AVASTIN+IV&monotype=default | ||
| title = Avastin IV: doses, uses and warnings | | title = Avastin IV: doses, uses and warnings | ||
| publisher = Medscape/American Society of Health System Pharmacists}}</ref> | | publisher = Medscape/American Society of Health System Pharmacists}}</ref> | ||
== | ==Studies after release== | ||
It had received accelerated approval based on the [[surrogate marker]] that it decreased tumor size. On 16 July 2010, the FDA announced "FDA reviewers said two follow-up studies recently submitted by Roche failed to show that Avastin significantly extended lives compared to chemotherapy alone Additionally, the FDA said that in follow-up studies the drug did not slow tumor growth to the same degree as in earlier studies. Patients taking Avastin showed significantly more side effects, including high blood pressure, fatigue and abnormal white blood cell levels." <ref name=AP>{{citation | It had received accelerated approval based on the [[surrogate marker]] that it decreased tumor size. On 16 July 2010, the FDA announced "FDA reviewers said two follow-up studies recently submitted by Roche failed to show that Avastin significantly extended lives compared to chemotherapy alone Additionally, the FDA said that in follow-up studies the drug did not slow tumor growth to the same degree as in earlier studies. Patients taking Avastin showed significantly more side effects, including high blood pressure, fatigue and abnormal white blood cell levels." <ref name=AP>{{citation | ||
| url = http://www.washingtonpost.com/wp-dyn/content/article/2010/07/17/AR2010071700813_pf.html | | url = http://www.washingtonpost.com/wp-dyn/content/article/2010/07/17/AR2010071700813_pf.html | ||
| Line 13: | Line 13: | ||
| title = FDA says breast cancer drug did not extend lives | | title = FDA says breast cancer drug did not extend lives | ||
| author = Matthew Perone}}</ref> | | author = Matthew Perone}}</ref> | ||
A presentation at the June 2010 meeting of the [[American Society for Clinical Oncology]] stated it improved progression-free survival, but not overall survival, in advanced ovarian cancer. The study used higher dosages than other trials, and the most effective trial arm used an induction and a subsequent maintenance dose.<ref>{{citation | |||
| url =http://www.medscape.com/viewarticle/723073 | |||
| title = Bevacizumab Boosts Progression-Free Survival in Ovarian Cancer | |||
| author = Roxanne Nelson | |||
| publisher = Medscape (coverage of American Society for Clinical Oncology) | |||
| date = 7 June 2010 | |||
}}</ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 13:49, 17 July 2010
Bevacizumab is an "anti-VEGF (i.e., vascular endothelial growth factor A (Entrez protein) monoclonal antibody consisting of humanized murine antibody with antigen-binding, complementary-determining regions from murine VEGF".[1] In the United States, it is marketed as Avastin by Genentech, a subsidiary of Roche Laboratories as an antineoplastic agent.
Indications
The U.S. Food and Drug Administration (FDA) recognizes it as indicated for: glioblastoma multiforme, metastatic breast carcinoma, metastatic colorectal cancer, non-small cell lung cancer, and renal cell cardinoma. Common unlabeled uses are in anaplastic astrocytoma and ovarian carcinoma. [2]
Studies after release
It had received accelerated approval based on the surrogate marker that it decreased tumor size. On 16 July 2010, the FDA announced "FDA reviewers said two follow-up studies recently submitted by Roche failed to show that Avastin significantly extended lives compared to chemotherapy alone Additionally, the FDA said that in follow-up studies the drug did not slow tumor growth to the same degree as in earlier studies. Patients taking Avastin showed significantly more side effects, including high blood pressure, fatigue and abnormal white blood cell levels." [3]
A presentation at the June 2010 meeting of the American Society for Clinical Oncology stated it improved progression-free survival, but not overall survival, in advanced ovarian cancer. The study used higher dosages than other trials, and the most effective trial arm used an induction and a subsequent maintenance dose.[4]
References
- ↑ Anonymous (2024), Bevacizumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Avastin IV: doses, uses and warnings, Medscape/American Society of Health System Pharmacists
- ↑ Matthew Perone (17 July 2010), FDA says breast cancer drug did not extend lives, Associated Press in Washington Post
- ↑ Roxanne Nelson (7 June 2010), Bevacizumab Boosts Progression-Free Survival in Ovarian Cancer, Medscape (coverage of American Society for Clinical Oncology)